Top Page
SynAct Pharma AB
(SYNACT)
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
SynAct Pharma AB Business Overview & Revenue Model
SynAct Pharma AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K | 0.00 |
| EBITDA | -103.55M | -15.40M | -222.70M | -105.71M | -76.62M | -30.90M |
| Net Income | -91.07M | -82.40M | -215.81M | -99.20M | -69.30M | -26.55M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 270.52M | 228.02M | 142.60M | 38.37M | 21.59M |
| Cash, Cash Equivalents and Short-Term Investments | 68.89M | 61.21M | 62.40M | 108.25M | 24.00M | 14.55M |
| Total Debt | 1.54M | 1.88M | 637.00K | 2.06M | 3.09M | 0.00 |
| Total Liabilities | 47.18M | 56.35M | 51.83M | 16.08M | 17.50M | 5.72M |
| Stockholders Equity | 196.41M | 214.17M | 176.19M | 126.52M | 20.87M | 15.87M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Operating Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Investing Cash Flow | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K | -93.00K |
| Financing Cash Flow | 40.13M | 87.41M | 53.98M | 200.71M | 74.32M | 44.72M |
SynAct Pharma AB Technical Analysis
SynAct Pharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr2.93B | 4.62 | 167.77% | ― | 2687.51% | ― | |
67 Neutral | kr1.24B | 9.82 | 81.19% | ― | ― | ― | |
56 Neutral | kr1.18B | -10.16 | -58.41% | ― | ― | 48.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.18B | -3.97 | ― | ― | 131.20% | 32.28% | |
47 Neutral | kr396.46M | -3.64 | -79.60% | ― | ― | 31.62% | |
42 Neutral | kr32.17M | -0.21 | -199.25% | ― | ― | 0.30% |
SynAct Pharma AB Corporate Events
SynAct Pharma’s board and management have voluntarily signed lock-up agreements preventing them from selling or otherwise disposing of their shares and related securities between 1 January and 30 June 2026, allowing only customary exceptions. The move comes as the company approaches key clinical milestones, including near-completion of patient recruitment and upcoming topline data from its Phase 2b ADVANCE trial in rheumatoid arthritis and a Phase 2a study in dengue virus, and is intended to underscore leadership’s confidence in SynAct’s strategy, support transparency around market-sensitive results, and signal commitment to long-term value creation for shareholders and potential partners.
SynAct Pharma AB announced that its top leadership, including the CEO, CSO, CBO, and Chairman of the Board, have collectively acquired 12,028 shares in the company on Nasdaq Stockholm, signaling internal confidence in the firm’s prospects. Management highlighted that recruitment in the company’s lead program in rheumatoid arthritis is nearing completion and that it is preparing to initiate a clinical trial in viral infection, underscoring an active late-stage pipeline and setting expectations for a data-rich 2026 that could be significant for investors and the company’s positioning within inflammatory disease therapeutics.
SynAct Pharma AB has announced the appointment of its Nomination Committee in preparation for the Annual General Meeting (AGM) 2026. The committee, comprising representatives from the three largest shareholders and the chairman of the Board, is tasked with proposing candidates for board positions and determining remuneration, reflecting the company’s commitment to transparent governance and stakeholder engagement.
SynAct Pharma announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco, where CEO Jeppe Øvlesen will engage with potential partners and investors. The conference presents a significant opportunity for SynAct Pharma to discuss advancements in their resomelagon treatment for rheumatoid arthritis and host-directed therapy for viral infections, potentially impacting their market positioning and stakeholder interests.
SynAct Pharma AB held an Extraordinary General Meeting where key resolutions were passed, including the implementation of an employee share option program and authorization for the Board to manage the acquisition and transfer of own shares. These measures aim to secure long-term commitment from employees and enhance the company’s capital structure, potentially increasing shareholder value.
SynAct Pharma AB announced its participation in the Redeye Autoimmune and Inflammatory Diseases event in Stockholm, where the company’s Chief Business Officer, Mads Bjerregaard, will present updates on their lead compound, resomelagon. This potential first-in-class, non-suppressive immune system modulator is being developed for treating rheumatoid arthritis and acute inflammation due to viral infections, highlighting SynAct’s innovative approach in the field of immunology.
SynAct Pharma AB has made significant progress in its Phase 2b ADVANCE study for Resomelagon, a treatment for Rheumatoid Arthritis, by randomizing 190 out of 240 patients. The study aims to evaluate the efficacy of Resomelagon in combination with methotrexate therapy, potentially offering a safer and effective alternative to current treatments, which could impact the future management of Rheumatoid Arthritis, a condition projected to affect up to 32 million people by 2050.
SynAct Pharma AB announced its participation in the BioEurope 2025 conference in Vienna, a major event for the life sciences sector with over 5,700 delegates. The company aims to discuss potential collaborations for its lead program, Resomelagon, a non-suppressive immune modulation therapy for rheumatoid arthritis and inflammation due to viral infections, highlighting its potential to support millions of patients.
SynAct Pharma AB released its interim report for the third quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing research and development efforts in inflammatory diseases, which are crucial for its market positioning and stakeholder interests.
SynAct Pharma AB has announced an Extraordinary General Meeting scheduled for November 27, 2025, in Stockholm, Sweden. The meeting will address several key resolutions, including the introduction of an employee share option program (ESOP 2025), a directed issue of warrants, and authorization for the acquisition and transfer of own shares. These initiatives are likely aimed at enhancing employee engagement and optimizing the company’s capital structure, potentially impacting shareholder value and market positioning.
SynAct Pharma AB has announced that Edison Investment Research Ltd., a UK-based firm, has initiated coverage of the company. This collaboration is expected to enhance SynAct Pharma’s visibility in the pharma and biotech industry, potentially impacting its market positioning and providing stakeholders with valuable insights into its operations.